Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients ; day:25 ; month:7 ; year:2017 ; pages:1-10
Wiener klinische Wochenschrift ; (25.7.2017), 1-10
- Urheber
-
Chromy, David
- Beteiligte Personen und Organisationen
-
Schwabl, Philipp
Bucsics, Theresa
Scheiner, Bernhard
Strassl, Robert
Mayer, Florian
Aichelburg, Maximilian C.
Grabmeier-Pfistershammer, Katharina
Trauner, Michael
Peck-Radosavljevic, Markus
Reiberger, Thomas
Mandorfer, Mattias
SpringerLink (Online service)
- DOI
-
10.1007/s00508-017-1231-x
- URN
-
urn:nbn:de:1111-201712214197
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chromy, David
- Schwabl, Philipp
- Bucsics, Theresa
- Scheiner, Bernhard
- Strassl, Robert
- Mayer, Florian
- Aichelburg, Maximilian C.
- Grabmeier-Pfistershammer, Katharina
- Trauner, Michael
- Peck-Radosavljevic, Markus
- Reiberger, Thomas
- Mandorfer, Mattias
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hepatitis C treatment initiation in HIV-HCV coinfected patients
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients
Hepatitis C treatment initiation in HIV-HCV coinfected patients
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients
Hepatitis C treatment initiation in HIV-HCV coinfected patients
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients
Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients